Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents

(2011) Roberto Calcedo et al.   Clinical and Vaccine Immunology

Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia

(2011) C Li et al.   GENE THERAPY

Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register

(2011) M. M. SOLIMAN et al.   JOURNAL OF RHEUMATOLOGY

A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8

(2011) Virginie Monteilhet et al.   MOLECULAR THERAPY

Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

(2011) Federico Mingozzi et al.   NATURE REVIEWS GENETICS

The state of therapy for removal of alloantibody producing plasma cells in transplantation

(2011) Matthew J. Everly et al.   SEMINARS IN IMMUNOLOGY

The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity

(2010) Hiroki Takahashi et al.   AUTOIMMUNITY REVIEWS

Prospects for gene therapy in inflammatory arthritis

(2010) Christian Jorgensen et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

(2010) Sylvie Boutin et al.   HUMAN GENE THERAPY

Phenotypic Changes of Lymphocytes in Patients with Systemic Lupus Erythematosus Who Are in Longterm Remission After B Cell Depletion Therapy with Rituximab

(2010) S. IWATA et al.   JOURNAL OF RHEUMATOLOGY

Safety and Efficacy of Subretinal Readministration of a Viral Vector in Large Animals to Treat Congenital Blindness

(2010) D. Amado et al.   Science Translational Medicine

A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis

(2009) B J F van den Bemt et al.   ANNALS OF THE RHEUMATIC DISEASES

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated Viruses

(2009) Roberto Calcedo et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study

(2009) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial

(2009) Albert M Maguire et al.   LANCET

Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy

(2009) M. L. Brantly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rituximab treatment in rheumatoid arthritis: how does it work?

(2009) Maria JH Boumans et al.   ARTHRITIS RESEARCH & THERAPY

Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor   antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Intramuscular Administration of AAV1-Lipoprotein Lipase S447X Lowers Triglycerides in Lipoprotein Lipase–Deficient Patients

(2008) Erik S. Stroes et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX

(2008) J. Sun et al.   BLOOD

Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis

(2008) Albert M. Maguire et al.   NEW ENGLAND JOURNAL OF MEDICINE